Kailera Therapeutics closed at $12.80 on Nov 4, up 1.75%, 8.2% below its highest close since Sep 11. Volume of 651.0K shares was 0.57× its 20-day average (below normal).
Split-adjusted performance: +18.2% over one month.
Short interest was 8.3M shares at the Oct 15 settlement, down 4.2% from the prior report (9.1% of float, 5.7 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| KLRAKailera Therapeutics | $12.80 | +1.75% | — | — | — | — | $1.66B | |
| NUVBNuvation Bio | $4.73 | +0.85% | −6.2% | +555.6% | −198.3% | — | $1.66B | Compare |
| ANIPANI Pharmaceuticals | $71.65 | −0.87% | −14.8% | +25.9% | 8.6% | 16.5 | $1.65B | Compare |
| SUPNSupernus | $28.21 | +0.21% | −45.2% | +18.0% | 9.2% | — | $1.64B | Compare |
| RAREUltragenyx Pharmaceutical | $17.16 | +3.19% | −33.8% | +28.1% | −43.0% | — | $1.69B | Compare |
| PAHCPhibro Animal Health | $39.43 | +4.73% | −32.6% | +4.8% | 5.5% | 16.1 | $1.60B | Compare |
| QUREuniQure | $23.03 | −3.52% | +0.9% | +11.0% | −1387.8% | — | $1.60B | Compare |
| NRIXNurix Therapeutics | $15.95 | −38.23% | −5.5% | +8426.3% | 81.7% | 5.9 | $1.74B | Compare |
| OCULOcular Therapeutix | $7.14 | +4.69% | −26.5% | +0.1% | −584.5% | — | $1.57B | Compare |
Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
